Xenon Pharmaceuticals Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Xenon Pharmaceuticals (XENE) granted 13,450 share options and 7,850 RSUs to five new employees, approved by the Board's Compensation Committee. Options have a $61.93 exercise price and vest over four years. RSUs vest annually over four years. Both are subject to continued employment.
Xenon Pharmaceuticals (XENE) will present Phase 3 data for azetukalner, a KV7 channel opener, at the 16th European Epilepsy Congress. The company plans six presentations, including topline X-TOLE2 study results for focal onset seizures and mechanistic characterization of azetukalner's potential additive effects with other antiseizure medications. Xenon aims to highlight azetukalner's differentiated attributes and its potential to enhance seizure control through rational polytherapy.
Xenon Pharmaceuticals (XENE) reported Q2 2026 results and discussed clinical progress. Cash was $1,245.1M as of June 30, 2026, expected to fund operations into 2029. Q2 net loss was $110.7M ($1.11/share). Management said Azetukalner NDA submission for focal onset seizures is on track for Q3 2026, with Phase 3 programs in major and bipolar depression and pain pipeline updates.
Over the past 7 days, alphai's AI scored 1 news story mentioning XENE (Xenon Pharmaceuticals Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent XENE coverage spans earnings, sector analysis and financial news.
In the last 30 days, XENE insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.1M). The most active reporter was KENNEY CHRISTOPHER JOHN, Chief Medical Officer, with 2 filings. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor dilution from employee equity awards; limited immediate price impact.
Positive Phase 3 data could lift XENE sharply if results meet expectations.
Near-term focus is Azetukalner regulatory timing and ongoing Phase 3 enrollment, with cash runway supporting multiple programs into 2029.
This is an insider open-market sale with no 10b5-1 plan disclosed, but it is not a fundamental company update.
Regional licensing structure can improve commercialization prospects and reduce execution burden for Xgene in China/HK/Mac.
alphai scores every news story that mentions XENE with an AI model for sentiment and relevance, and aggregates insider trades from Xenon Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xenon Pharmaceuticals (XENE) granted 13,450 share options and 7,850 RSUs to five new employees, approved by the Board's Compensation Committee. Options have a $61.93 exercise price and vest over four years. RSUs vest annually over four years. Both are subject to continued employment.
1 min readXenon Pharmaceuticals (XENE) will present Phase 3 data for azetukalner, a KV7 channel opener, at the 16th European Epilepsy Congress. The company plans six presentations, including topline X-TOLE2 study results for focal onset seizures and mechanistic characterization of azetukalner's potential additive effects with other antiseizure medications. Xenon aims to highlight azetukalner's differentiated attributes and its potential to enhance seizure control through rational polytherapy.
2 min readXenon Pharmaceuticals (XENE) reported Q2 2026 results and discussed clinical progress. Cash was $1,245.1M as of June 30, 2026, expected to fund operations into 2029. Q2 net loss was $110.7M ($1.11/share). Management said Azetukalner NDA submission for focal onset seizures is on track for Q3 2026, with Phase 3 programs in major and bipolar depression and pain pipeline updates.
7 min readGANNON STEVEN sold 10,000 shares of Xenon Pharmaceuticals Inc. (XENE) at $64.06 ($0.64M total) on 2026-08-11.
1 min readDelveInsight’s 2026 report says 45+ pharma companies are developing 52+ postoperative pain management drugs across clinical stages. It highlights late and mid-stage programs including Ensysce’s PF614 (Phase III), Xgene’s XG005 (II/III), and Jiangsu Hengrui’s HRS-2129 (II/III). It also cites AbbVie’s April 2026 deal with Haisco (USD 30M upfront, up to USD 705M milestones) and recent trial/enrollment updates.
7 min readXenon Pharmaceuticals reported Q2 revenue changes by region, with Americas up 6% and EMEA up 15% excluding non-recurring license and royalty revenue, while Asia-Pacific fell 19% versus a prior-year China pull-forward. Q2 gross margin rose to 74%. Operating expenses were $132.1M. Cash totaled $552M. Full-year 2026 revenue outlook raised to $610M-$630M.
6 min readXenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q2 2026 Financial Results and Provides Business Update • NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA • Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll • Three Phase 3 studies of azetuk
6 min readThe article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.
7 min readVANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026.
1 min readXenon Pharmaceuticals (Nasdaq: XENE) said it granted inducement equity to four new non-officer employees effective July 1, 2026: 20,200 share options and 11,850 RSUs. Options have a $60.30 exercise price (July 1 close) and vest over four years; RSUs vest 25% annually over four years, subject to continued service, per Nasdaq Rule 5635(c)(4).
2 min read
